Dr. Eric Biron, PhD, is a Regular Researcher at the CHU de Québec Research Center and Full Professor at the Faculty of Pharmacy of Laval University. Recognized for his contributions in peptide chemistry, combinatorial chemistry and antimicrobial peptides, Dr. Biron is particularly interested in the use of peptidomimetic macrocycles and heterocycles in medicinal chemistry. His research focuses on the discovery and development of novel therapeutic agents for the treatment of infectious diseases and cancers.

Discovery and development of new antibacterial agents

The alarming spread of antibiotic resistance has become a major problem in the treatment of bacterial infections. In this context, Dr. Biron is particularly interested in bacteriocins, a family of low molecular weight proteins produced by several bacteria, with strong antimicrobial activity. As they exhibit inhibitory activities against a large number of clinically important pathogenic bacteria, bacteriocins are increasingly considered as a promising substitute to antibiotics.

Based on their enormous potential in the pharmaceutical and medical areas, Dr. Biron’s laboratory is developing novel synthetic approaches to produce bacteriocins, and uses peptidomimetic strategies to optimize their pharmacological properties, improve their pharmacokinetic profile, and modify their spectrum of activity.

Development of new anti-cancer agents

Despite the progress made in various therapeutic approaches, the effectiveness of main anti-cancer therapies has reached a critical plateau in the treatment of several cancers. As a result, the demand for innovative and effective compounds with new modes of action is growing rapidly. In this context, Dr. Biron’s laboratory uses combinatorial chemistry to prepare libraries with high molecular diversity and perform target-based or phenotypic screenings to discover promising anti-cancer molecules.

In another approach, Dr. Biron is interested in the addiction of cancer cells to some multifunctional proteins that also play an important role in the resistance to treatment. In this case, Dr. Biron’s laboratory aims to develop functional inhibitors of these proteins through rational design, and peptidomimetic approaches.

2705, boulevard Laurier
Québec, Québec
Canada G1V 4G2
47 entries « 5 of 5 »

Sukopp M, Schwab R, Marinelli L, Biron E, Heller M, Varkondi E, Pap A, Novellino E, Keri G, Kessler H

Structure-activity relationship studies optimizing the antiproliferative activity of novel cyclic somatostatin analogues containing a restrained cyclic beta-amino acid

Journal Article

J Med Chem, 48 (8), 2005.

Abstract | Links:

Biron E, Otis F, Meillon JC, Robitaille M, Lamothe J, Van Hove P, Cormier ME, Voyer N

Design, synthesis, and characterization of peptide nanostructures having ion channel activity

Journal Article

Bioorg Med Chem, 12 (6), 2004.

Abstract | Links:

Vandenburg YR, Smith BD, Biron E, Voyer N

Membrane disruption ability of facially amphiphilic helical peptides

Journal Article

Chem Commun (Camb), (16), 2002.

Abstract | Links:

Voyer N, Côté S, Biron E, Beaumont M, Chaput M, Levac S

Chiral Recognition of Carboxylic Acids by Bis-Crown Ether Peptides

Journal Article

J Supramol Chem, 1 (1), 2001.

Biron E, Voyer N, Meillon JC, Cormier ME, Auger M

Conformational and orientation studies of artificial ion channels incorporated into lipid bilayers

Journal Article

Biopolymers, 55 (5), 2000.

Abstract | Links:

Meillon JC, Voyer N, Biron E, Sanschagrin F, Stoddart JF

Thermoregulated Optical Properties of Peptidic Pseudorotaxanes

Journal Article

Angew Chem Int Ed Engl, 39 (1), 2000.

Abstract | Links:

Boulanger Y, Biron E, Khiat A, Fournier A

Conformational analysis of biologically active truncated linear analogs of endothelin-1 using NMR and molecular modeling

Journal Article

J Pept Res, 53 (2), 1999.

Abstract | Links:

47 entries « 5 of 5 »
Signaler des ajouts ou des modifications

Active projects

  • Dérivatisation de triterpènes naturels par réactions multicomposantes pour le développement de nouveaux composés bioactifs biosourcés, from 2023-08-15 to 2027-08-14
  • Exploiter l'addiction des bactéries au fer: Conception de nouvelles molécules hybrides bactériocine-sidérophore et évaluation de leur potentiel comme alternative aux antibiotiques, from 2021-04-01 to 2024-03-31
  • Institut sur la nutrition et les aliments fonctionnels (INAF), from 2017-04-01 to 2024-03-31
  • New approaches for the design and synthesis of heterocyclic and macrocyclic bioactive peptidomimetics, from 2020-04-01 to 2025-03-31

Recently finished projects

  • Design et synthèse d'acides aminés biosourcés pour la préparation de nouveaux triterpènes fonctionnalisés et de peptides conjugés, from 2020-01-13 to 2022-03-12
  • Développement de nouvelles molécules bioactives et d’acides aminés biosourcés par dérivatisation de triterpènes naturels, from 2022-05-01 to 2023-06-30
  • La conception de nouveaux agents thérapeutiques et la résonance magnétique nucléaire, from 2022-01-01 to 2023-05-31
  • Laboratoire de pointe en chimie peptidique et biomoléculaire pour la découverte et la conception de molécules bioactives, from 2022-04-01 to 2023-09-28
  • Valorisation de triterpènes naturels par dérivatisation pour le développement de nouvelles molécules bioactives biosourcées, from 2021-11-15 to 2022-11-14
Data provided by the Université Laval research projects registery